(Q34481727)

2 August 2017

1 reference

title

Recent advances in the treatment of epithelial ovarian cancer (English)

1 reference

2 August 2017

1 reference

Harries M

1

1 reference

PubMed ID

11772280

2 August 2017

Kaye SB

series ordinal

2

1 reference

PubMed ID

11772280

2 August 2017

language of work or name

English

0 references

publication date

1 September 2001

1 reference

Expert Opinion on Investigational Drugs

2 August 2017

1 reference

2 August 2017

10

1 reference

2 August 2017

1715-1724

1 reference

2 August 2017

9

1 reference

Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends

2 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase II study of liposomal doxorubicin in advanced gynecologic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Epirubicin for pretreated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.9.1715

10.1517/13543784.10.9.1715

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11772280